At the end of the second quarter of 2015, the hedge fund JFS Wealth Advisors, LLC reported a total value of its portfolio of $194,802,000 with a decrease of 8.64% since the previous quarter.
During Q2 2015, the hedge fund bought 39 new stocks and increased 111 stakes. The following are the most heavily weighted buys of U.S. companies during the quarter.
The fund bought 35,000 shares of Alliance Holdings Gp Lp (AHGP) with an impact of 0.70% on its portfolio. The company was formed to own and control Alliance Resource Management GP, LLC, the managing general partner of Alliance Resource Partners LP. The Company completed its initial public offering in May 2006. The Company's ARLP Partnership is a diversified producer and marketer of coal to U.S. utilities and industrial users. Its ARLP Partnership operates ten underground mining complexes in Illinois, Indiana, Kentucky, Maryland and West Virginia.
The stock is trading with a very low P/E(ttm) ratio of 7.81 (that is ranked higher than 76% of other companies in the Global Coal industry) and the price has dropped by 47% during the last 12 months, but has risen by 48% during the last 10 years.
The company has profitability and growth rated 9/10; it has positive returns with a ROE of 51.33% and a ROA of 12.74% that are outperforming 92% of the other companies in the same industry.
The only guru holding shares of the company is Jim Simons (Trades, Portfolio) with 0.18% of shares outstanding of the company
It bought 21,493 shares of Williams Partners LP (WPZ) with an impact of 0.53% on its portfolio. The company is an energy infrastructure company focused on connecting North America's hydrocarbon resource plays to markets for natural gas, natural gas liquids (NGLs) and olefins.
The stock is trading with a very high P/E(ttm) ratio of 87.29 (that is ranked lower than 89% of other companies in the Global Oil & Gas industry) and the price has dropped by 19% during the last 12 months but has risen by 111% during the last 10 years.
The company has profitability and growth rated 6/10; it has positive returns with a ROE of 0.41% and a ROA of 2.97% that are underperforming 83% of the other companies in the same industry.
Jim Simons (Trades, Portfolio) is the main shareholder of the company with 0.18% of shares outstanding, followed by Howard Marks (Trades, Portfolio) with 0.02% and John Hussman (Trades, Portfolio) who holds less than 0.01% of outstanding shares of the company.
The fund bought 12,721 shares of Mylan NV (MYL) with an impact of 0.44% on its portfolio. The company together with its subsidiaries, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company offers 1,300 marketed products, to customers in 140 countries and territories. It also operates a research and development network that delivers a robust product pipeline.
The stock is trading with a very high P/E(ttm) ratio of 25.13 (that is ranked higher than 64% of other companies in the Global Drug Manufacturers – Specialty & Generic industry) and the price has risen by 13% during the last 12 months and by 204% during the last 10 years.
The company has profitability and growth rated 7/10; it has positive returns with a ROE of 19.57% and a ROA of 5.17% that are outperforming the 60% of the other companies in the same industry.
Vanguard Health Care Fund (Trades, Portfolio) is the main hedge fund holding shares of the company with 3.24% of outstanding shares, followed by John Paulson (Trades, Portfolio) with 3.05% and Pioneer Investments (Trades, Portfolio) with 0.17%.
It bought 5,627 shares of Apache Corp (APA) with an impact of 0.17% on its portfolio. It is an independent energy company that explores for, develops, and produces natural gas, crude oil, and natural gas liquids. It has exploration and production interests in six countries: the U.S., Canada, Egypt, Australia, the U.K. North Sea (North Sea), and Argentina.
The stock is trading with a very high forward P/E ratio of 66.23 (that is ranked lower than 76% of other companies in the Global Oil & Gas E&P industry) and the price has dropped by 54% during the last 12 months and by 34% during the last 10 years.
The company has profitability and growth rated 6/10 but with very negative returns: ROE of -35.78% and a ROA of -17.87%% that are underperforming the 70% of the other companies in the same industry.
Dodge & Cox is the main hedge fund holding shares of the company with 8.27% of outstanding shares or 1.73% of its total assets. The second largest shareholder is Bill Nygren (Trades, Portfolio) with 2.19% (2.97% of his total assets) followed by Brian Rogers (Trades, Portfolio) with 1.86% of outstanding shares, or 1.55% of his total assets.
It bought 3,213 shares of Medtronic Plc (MDT) with an impact of 0.12% on its portfolio. The Company is a medical technology company - alleviating pain, restoring health, and extending life for millions of people around the world. Its primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, and ear, nose, and throat and diabetes conditions.
The stock is trading with a P/E(ttm) ratio of 29.15 (that is ranked lower than 51% of other companies in the Global Medical Devices industry) and the price has risen by 28% during the last 12 months and by 46% during the last 10 years.
The company has profitability and growth rated 7/10 but with positive returns: ROE of 10.17% and a ROA of 4.84% that are outperforming the 66% of the other companies in the same industry.
James Barrow (Trades, Portfolio) is the main shareholder of the company with 2.25% of outstanding shares, followed by Vanguard Health Care Fund (Trades, Portfolio) with 1.33% and PRIMECAP Management (Trades, Portfolio) with 1.24%.
